[1] |
Chugh SS,Havmoeller R,Narayanan K,et al.Worldwide epidemiology of atrial fibrillation:a Global Burden of Disease 2010 Study[J].Circulation,2014,129(8):837-847.
|
[2] |
周自强,胡大一,陈捷,等.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004(7):15-18.
|
[3] |
Ball J,Carrington MJ,Mcmurray JJ,et al.Atrial fibrillation:profile and burden of an evolving epidemic in the 21stcentury[J].Int JCardiol,2013,167(5):1807-1824.
|
[4] |
Wang TJ,Larson MG,Levy D,et al.Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality:the Framingham Heart Study[J].Circulation,2003,107(23):2920-2925.
|
[5] |
Wolf PA,Dawber TR,Thomas HJ,et al.Epidemiologic assessment of chronic atrial fibrillation and risk of stroke:the Framingham study[J].Neurology,1978,28(10):973-977.
|
[6] |
Andersson T,Magnuson A,Bryngelsson IL,et al.All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995~2008:a Swedish nationwide long-term case-control study[J].Eur Heart J,2013,34(14):1061-1067.
|
[8] |
黄从新,张澍,黄德嘉,等.心房颤动:目前的认识和治疗建议-2015[J].中国心脏起搏与心电生理杂志,2015(5):377-434.
|
[10] |
Flegel KM,Shipley MJ,Rose G.Risk of stroke in nonrheumatic atrial fibrillation[J].Lancet,1987,1(8532):526-529.
|
[13] |
王春娟,王春雪,王拥军,等.中国非瓣膜性心房颤动患者华法林使用不足的相关因素分析[J].中国新药杂志,2012(11):1203-1209.
|
[21] |
赵世华.齐头并进,共谱新篇章:论影像学在结构性心脏病介入治疗中的指导价值[J].中华心血管病杂志,2016,44(10):830-832.
|
[7] |
Magnussen C,Niiranen TJ,Ojeda FM,et al.Sex Differences and Similarities in Atrial Fibrillation Epidemiology,Risk Factors,and Mortality in Community Cohorts:ResultsFrom the BiomarCaRE Consortium(Biomarker for Cardiovascular Risk Assessment in Europe)[J].Circulation,2017,136(17):1588-1597.
|
[9] |
January CT,Wann LS,Alpert JS,et al.2014 AHA/ACC/HRS guideline for themanagement of patientswith atrial fibrillation:executive summary:a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society[J].Circulation,2014,130(23):2071-2104.
|
[11] |
Pisters R,Lane DA,NieuwlaatR,etal.A novel user-friendly score(HAS-BLED)to assess1-year risk ofmajor bleeding in patientswith atrial fibrillation:the Euro Heart Survey[J].Chest,2010,138(5):1093-1100.
|
[12] |
Hart RG,Pearce LA,Aguilar MI.Meta-analysis:antithrombotic therapy to prevent stroke in patientswho have nonvalvular atrial fibrillation[J].Ann Intern Med,2007,146(12):857-867.
|
[14] |
Ruff CT,Giugliano RP,Braunwald E,et al.Comparison of the efficacy and safety of new oral anticoagulantswith warfarin in patients with atrial fibrillation:ameta-analysis of randomised trials[J].Lancet,2014,383(9921):955-962.
|
[15] |
Ntaios G,Papavasileiou V,Makaritsis K,et al.Real-world setting comparison of Nonvitamin-K antagonist oral Anticoagulants versus Vitamin-K antagonists for stroke prevention in atrial fibrillation:a Systematic Review and Meta-Analysis[J].Stroke,2017,48(9):2494-2503.
|
[16] |
Cha MJ,Choi EK,Han KD,et al.Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Atrial Fibrillation[J].Stroke,2017,48(11): 3040-3048.
|
[17] |
Kirchhof P,Benussi S,Kotecha D,et al.2016 ESC Guidelines for themanagement of atrial fibrillation developed in collaborationwith EACTS[J].Eur JCardiothorac Surg,2016,50(5):e1-e88.
|
[18] |
Holmes DR,Reddy VY,Turi ZG,etal.Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention ofstroke in patientswith atrial fibrillation:a randomised non-inferiority trial[J].Lancet,2009,374(9689):534-542.
|
[19] |
Reddy VY,Holmes D,Doshi SK,et al.Safety of percutaneous leftatrialappendage closure:results from theWatchman Left Atrial Appendage System for Embolic Protection in Patientswith AF(PROTECT AF)clinical trial and the Continued Access Registry[J].Circulation,2011,123(4):417-424.
|
[20] |
Holmes DJ,Kar S,Price MJ,et al.Prospective randomized evaluation of theWatchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy:the PREVAIL trial[J].JAm Coll Cardiol,2014,64(1):1-12.
|
[22] |
Reddy VY,Doshi SK,Kar S,et al.5-year outcomes after left atrial appendage closure:From the PREVAIL and PROTECTAFTrials[J].JAm Coll Cardiol,2017,70(24):2964-2975.
|
[23] |
Wyse DG,Waldo AL,Dimarco JP,et al.A comparison of rate control and rhythm control in patients with atrial fibrillation[J].N Engl JMed,2002,347(23):1825-1833.
|
[24] |
Steinberg JS,Sadaniantz A,Kron J,etal.Analysis of causespecific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management(AFFIRM)study[J].Circulation,2004,109(16):1973-1980.
|
[25] |
Hakalahti A,Biancari F,Nielsen JC,et al.Radiofrequency ablation vs.antiarrhythmic drug therapy as first line treatment of symptomatic atrial fibrillation:systematic review and meta-analysis[J].Europace,2015,17(3):370-378.
|
[26] |
Haissaguerre M,Jais P,Shah DC,et al.Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins[J].N Engl JMed,1998,339(10):659-666.
|
[27] |
Ganesan AN,Shipp NJ,BrooksAG,etal.Long-term Outcomes of Catheter Ablation of Atrial Fibrillation:a Systematic Review and Meta-analysis[J].JAm HeartAssoc,2013,2(2):e4549.
|
[28] |
Bunch TJ,Crandall BG,Weiss JP,etal.Patients treated with catheterablation foratrial fibrillationhave long-term ratesof death,stroke,and dementia similar to patientswithout atrial fibrillation[J].JCardiovasc Electrophysiol,2011,22(8):839-845.
|
[29] |
Calkins H,Kuck KH,Cappato R,et al.2012 HRS/EHRA/ECASExpert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation:recommendations for patient selection,procedural techniques,patientmanagement and follow-up,definitions,endpoints,and research trial design[J].Europace,2012,14(4):528-606.
|